Re: Equity investment Fair Value in Turkey ,
 John,

Please, give me another day to elaborate. It's quite hectic here.

Vince


   
	Enron Capital & Trade Resources Corp. - Europe
	
	From:  John Bottomley                           06/21/2000 03:41 AM
	

To: Vince J Kaminski/HOU/ECT@ECT
cc:  
Subject: Re: Equity investment Fair Value in Turkey  

Vince,

Any further thoughts on your end?

John



Vince J Kaminski
19/06/2000 15:45
To: John Bottomley/LON/ECT@ECT
cc: Dale Surbey/LON/ECT@ECT, Vince J Kaminski/HOU/ECT@ECT, Stinson 
Gibner/HOU/ECT@ECT 

Subject: Re: Equity investment Fair Value in Turkey  

John,

It seems to me that using a risk-free rate is not appropriate. I shall 
elaborate on my 
position and send you a longer message this afternoon (my time).

Vince



   
	Enron Capital & Trade Resources Corp. - Europe
	
	From:  John Bottomley                           06/19/2000 05:55 AM
	

To: Vince J Kaminski/HOU/ECT@ECT
cc: John Sherriff/LON/ECT@ECT, Dale Surbey/LON/ECT@ECT 
Subject: Equity investment Fair Value in Turkey

Vince,

John Sherriff recommended that I contact you regarding an interesting (and 
potentially contentious) option valuation issue we are currently dealing with 
in London.  We hold longish term options in a private company in Turkey which 
is currently seeking to IPO.  The issue we are discussing with RAC is which 
discount rate (i.e., risk-free? and if so Turkish or US?) should we use to 
value these options

First, some additional information.

Option characteristics:
-- 116,000 options (representing 9% of the company)
-- Term:  minimum of 3 years but possibly longer -- still being renegotiated
-- Strike price:  20% below the upcoming IPO price (either priced in US$ or 
Turkish Lire)

We currently hold the above number of options with a fixed price of $118.75 
per option but 34,800 expire on July 15, 2000 with the remainder expiring on 
December 15, 2000.  The company's investment bankers (ABN / AMRO Rothchilds) 
are concerned regarding the strike price because it values the company at 
$118 million and they believe the company is worth approx $300 million.  Due 
to such a large "valuation gap", they originally encouraged us to exercise 
all of the options by the end of June (IPO target date in late Sept / early 
Oct).  Our counter-proposal is to "swap" instrinsic value for time value by 
repricing the options strike higher while extending their term.

We are currently negotiating with RAC the most appropriate discount rate to 
use to value the options.  We are arguing that the US risk free is the most 
appropriate discount rate and their current position is that the company's 
historical senior debt cost (18%) is the more appropriate number to use 
(although admit that this is not justifiable -- only a proxy)

A few key points:
-- RAC is valuing the options via Crystal Ball simulations such that this "to 
be negotiated" discount rate is used to calculate the PV of the future 
options intrinsic value in 3 years
 (i.e., for Black-Scholes, a higher discount rate yields a higher value but 
the opposite is true using Crystal Ball simulation)
-- The model simulates both an IPO / no IPO case and in the case of no IPO we 
have put options for our equity priced at a fixed 17% return
-- The model assigns a 30% illiquidity discount
-- In the simulated cases where the options are out-of-the-money, we 
obviously do not exercise.

We understand that for Black-Scholes option valuation, one needs to be able 
to construct a comparable portfolio of cash flows using equity futures and 
the risk free in order for the valuation to hold.  And here is where we reach 
our difficulty:  since the company doesn't currently trade on a public market 
and since equity futures do not exist for Turkish equities, RAC is arguing 
that a US risk free is not appropriate to use.  Our argument is that the 
non-IPO scenario, a 30% illiquidity discount and a US$ based option 
volatility are already in the factored into the simulation.  As such, we feel 
RAC's approach is double counting.

If you managed to get through the above, your a patient man!  I'll give you a 
call today or tomorrow after you've had a chance to digest the information.

Regards,
John Bottomley
john.bottomley@enron.com